IP Library Granted Patent US 8,796,275
Granted Patent B2
US 8,796,275 · App. 12/510,593 · Granted Aug 5, 2014

Anti-malarial compounds

Inventors: Richard W. Scott (Radnor, PA); Doron Greenbaum (Philadelphia, PA); Dahui Liu (Wynnewood, PA); Xiaodong Fan (Center Valley, PA); Yongjiang Xu (Wayne, PA); Haizhong Tang (Lawrenceville, NJ); Ehab Khalil (Whitehouse Station, NJ)
Assignees: The Trustees of the University of Pennsylvania; Cellceutix Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,796,275
App. No.
12/510,593
Granted
Aug 5, 2014
Kind
B2
Abstract

The present invention provides tricyclic compounds, arylamide compounds, and other compounds, and compositions comprising the same, for treating malaria, and methods of treating malaria comprising administering such compounds to an animal.

Claims (84)

1. A compound of Formula I:

wherein:

X is N(R 9 ), O, S, S(═O), or S(═O) 2 ;

R 9 is H or C 1 -C 8 alkyl;

R 1 and R 2 are H;

R 3 and R 4 are, independently,

wherein each W, Y, and Z are, independently, C or N;

each R 5 is, independently, H or C 1 -C 8 alkoxy; and

each R 6 is, independently, the free base or salt form of —(CH 2 ) n —NH 2 , or —(CH 2 ) n —NH—(CH 2 ) n —NH 2 , or —(CH 2 ) n —NH—C(═NH)NH 2 , where each n is, independently, 1 to 8;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 wherein X is N(R 9 ), O, S, or S(═O) 2 .

3. The compound of claim 1 wherein R 3 and R 4 are,

independently

wherein each W, Y, and Z are C; or each Y and Z are C and each W is N.

4. The compound of claim 1 wherein:

X is NH, O, S, or S(═O) 2 ;

R 1 and R 2 are H;

R 3 and R 4 are, independently,

wherein each W, Y, and Z are, independently, C or N;

each R 5 is H; and

each R 6 is, independently, the free base or salt form of —(CH 2 ) n —NH 2 , where each n is, independently, 1 to 3.

5. The compounds of claim 1 chosen from:

or pharmaceutically acceptable salt thereof.

6. The compound of claim 1 which is:

or pharmaceutically acceptable salt thereof.

7. A compound of Formula I:

wherein:

X is NH or S;

R 1 and R 2 are H;

R 3 and R 4 are, independently,

wherein each W, Y, and Z are, independently, C or N;

each R 5 is, independently, H or C 1 -C 8 alkoxy; and

each R 6 is, independently, heterocycle, or the free base or salt form of —(CH 2 ) n —NH 2 , or —(CH 2 ) n —NH—(CH 2 ) n —NH 2 , or —(CH 2 ) n —NH—C(═NH)NH 2 , where each n is, independently, 1 to 8;

or a pharmaceutically acceptable salt thereof.

8. The compound of claim 7 which is

or a pharmaceutically acceptable salt thereof.

9. A compound of Formula I:

wherein:

X is N(R 9 ), O, S, S(═O), or S(═O) 2 ;

R 9 is H or C 1 -C 8 alkyl;

R 1 and R 2 are H;

R 3 and R 4 are, independently,

wherein each W, Y, and Z are, independently, C or N;

each R 5 is, independently, H or C 1 -C 8 alkoxy; and

each R 6 is piperazinyl or the free base or salt form of —(CH 2 ) n —NH 2 where each n is, independently, 1 to 3.

10. A compound of Formula I:

wherein:

X is NH, O, or S;

R 1 and R 2 are H;

R 3 and R 4 are

where each Z and Y are C, and each W is N; or each W, Y, and Z are C; each R 5 is H, and each R 6 is piperazinyl or the free base or salt form of —(CH 2 ) n —NH 2 , where each n is, independently, 1 to 3.

11. A pharmaceutical composition comprising the compound

or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

12. A method of treating malaria in an animal or killing or inhibiting the growth of a Plasmodium species comprising administering to the animal a therapeutically effective amount of a compound of Formula I or contacting the species with an effective amount of a compound of Formula I:

wherein:

X is N(R 9 ), O, S, S(═O), or S(═O) 2 ;

R 9 is H, C 1 -C 8 alkyl, C 1 -C 8 alkoxy, halo, OH, or CF 3 ;

R 1 and R 2 are, independently, H, C 1 -C 8 alkyl, C 1 -C 8 alkoxy, halo, OH, haloC 1 -C 8 alkyl, or CN;

R 3 and R 4 are, independently,

wherein each W, Y, and Z are, independently, C or N;

each R 5 and each R 6 are, independently, H, C 1 -C 8 alkyl, C 1 -C 8 alkoxy, halo, OH, CF 3 , aromatic group, heterocycle, or the free base or salt form of —(CH 2 ) n —NH 2 , —(CH 2 ) n —NH—(CH 2 ) n —NH 2 , or —(CH 2 ) n —NH—C(═NH)NH 2 , where each n is, independently, 1 to 8;

or a pharmaceutically acceptable salt thereof.

13. The method of claim 12 wherein X is N(R 9 ), O, S, or S(═O) 2 .

14. The method of claim 12 wherein R 1 and R 2 are, independently, H, C 1 -C 3 alkyl, C 1 -C 3 alkoxy, halo, OH, haloC 1 -C 3 alkyl, or CN.

15. The method of claim 12 wherein each R 5 is, independently, H, C 1 -C 8 alkyl, C 1 -C 8 alkoxy, halo, OH, CF 3 , or the free base or salt form of —(CH 2 ) n —NH 2 , —(CH 2 ) n —NH—(CH 2 ) n —NH 2 , or —(CH 2 ) n —NH—C(═NH)NH 2 , where each n is, independently, 1 to 8, and each R 6 is, independently, heterocycle or the free base or salt form of —(CH 2 ) n —NH 2 , —(CH 2 ) n —NH—(CH 2 ) n —NH 2 , or —(CH 2 ) n —NH—C(═NH)NH 2 , where each n is, independently, 1 to 8.

16. The method of claim 12 wherein:

X is NH, O, S, or S(═O) 2 ;

R 1 and R 2 are H;

R 3 and R 4 are, independently,

wherein each W, Y, and Z are, independently, C or N; and each R 5 and each R 6 are, independently, H, heterocycle, or the free base or salt form of —(CH 2 ) n —NH 2 , where each n is, independently, 1 to 3.

17. The method of claim 12 wherein the malaria is chloroquine-sensitive or chloroquine-resistant.

18. The method of claim 12 wherein the compound is chosen from:

or pharmaceutically acceptable salt thereof.

19. The method of claim 12 wherein the compound is:

or pharmaceutically acceptable salt thereof.

20. The method of claim 12 wherein:

X is N(R 9 ), O, S, S(═O), or S(═O) 2 ;

R 9 is H or C 1 -C 8 alkyl;

R 1 and R 2 are H;

R 3 and R 4 are, independently,

wherein each W, Y, and Z are, independently, C or N;

each R 5 is, independently, H or C 1 -C 8 alkoxy; and

each R 6 is, independently, the free base or salt form of —(CH 2 ) n —NH 2 , or —(CH 2 ) n —NH—(CH 2 ) n —NH 2 , or —(CH 2 ) n —NH—C(═NH)NH 2 , where each n is, independently, 1 to 8;

or a pharmaceutically acceptable salt thereof.

Assignments (3)
BANKRUPTCY COURT ORDER/ASSET PURCHASE AGREEMENT Recorded Nov 12, 2013
From: POLYMEDIX, INC.
To: CELLCEUTIX CORPORATION
Reel/Frame 031626/0732 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jan 17, 2013
From: POLYMEDIX, INC.; POLYMEDIX PHARMACEUTICALS, INC.
To: MIDCAP FINANCIAL SBIC, LP, AS ADMINISTRATIVE AGENT
Reel/Frame 029660/0322 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 17, 2009
From: SCOTT, RICHARD W.; LIU, DAHUI; FAN, XIAODONG; XU, YONGJIANG; TANG, HAIZHONG; KHALIL, EHAB; GREENBAUM, DORON
To: POLYMEDIX, INC.; THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Reel/Frame 023531/0650 →
Continuity (3)
Provisional Application 61162467 · Mar 23, 2009
Provisional Application 61083972 · Jul 28, 2008
Related Publication 20100081665A1 · Apr 1, 2010